Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24826754 | 1.00 | EGFR (0.40) | EGFRSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL24824609 | 0.87 | EGFR (0.40) | EGFRMEN1KMT2AKDM4E | |
| SCHEMBL30848800 | 0.87 | EGFR (0.40) | EGFRMEN1KMT2AKDM4E | |
| SCHEMBL30848806 | 0.86 | EGFR (0.51) | EGFRLPAR1CYP2C9ATRATRIP | |
| SCHEMBL24825129 | 0.86 | EGFR (0.51) | EGFRLPAR1CYP2C9ATRATRIP | |
| SCHEMBL24826464 | 0.85 | EGFR (0.50) | EGFR | |
| SCHEMBL30848835 | 0.85 | EGFR (0.50) | EGFR | |
| SCHEMBL24824597 | 0.84 | EGFR (0.39) | EGFRSMN1; SMN2LPAR1CYP2C9OPRK1 | |
| SCHEMBL30164839 | 0.84 | EGFR (0.39) | EGFRSMN1; SMN2LPAR1CYP2C9OPRK1 | |
| SCHEMBL24826755 | 0.84 | EGFR (0.39) | EGFRLPAR1CYP2C9OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271612-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |